Characteristic	Colonized (n = 125)			Not Colonized (n = 331)			Colonized vs. Not Colonized
Characteristic	Linezolid (n = 52)	Vancomycin (n = 73)	P Value	Linezolid (n = 187)	Vancomycin (n = 144)	P Value	P Value
Age, Mean (SD), y	45.9 (19.4)	49.7 (16.3)	0.24	49.8 (17.4)	49.3 (19.1)	0.80	0.44
Gender, Male, n (%)	31 (59.6)	49 (67.1)	0.45	100 (53.5)	78 (54.2)	0.91	0.06
Race, n (%) White Black Asian Other	35 (67.3) 10 (19.2) 0 7 (13.5)	50 (68.5) 16 (21.9) 0 7 (9.6)	0.77	135 (72.2) 26 (13.9) 2 (1.1) 24 (12.8)	95 (66.0) 16 (11.1) 2 (1.4) 31 (21.5)	0.19	0.06
Weight, kg (SD)	89.8 (36.9)	83.8 (23.6)	0.27	85.8 (24.8)	82.1 (29.1)	0.21	0.47
Prior Hospitalization, n (%)	23 (44.2)	28 (38.4)	0.58	77 (41.2)	63 (43.8)	0.66	0.83
Route of Initial Treatment, n (%) IV Oral	27 (51.9) 25 (48.1)	73 (100) 0	<0.01	103 (55.1) 84 (44.9)	144 (100) 0	<0.01	0.27
Concomitant Gram-Negative Coverage, n (%)	29 (55.8)	35 (47.9)	0.47	80 (42.8)	68 (47.2)	0.44	0.25
Corticosteroid Receipt, n (%)	5 (9.6)	5 (6.8)	0.74	10 (5.3)	11 (7.6)	0.50	0.54
Immunosuppressant Receipt, n (%)	0	0		1 (0.5)	1 (0.7)	1.0	1.0
Primary Diagnosis, n (%) Abscess Ulcer Surgical Wound Other	30 (57.7) 7 (13.5) 12 (23.1) 3 (5.8)	46 (63.0) 11 (15.1) 14 (19.2) 2 (2.7)	0.77	88 (47.1) 33 (17.6) 39 (20.9) 27 (14.4)	64 (44.4) 23 (16.0) 38 (26.4) 19 (13.2)	0.70	<0.01
Comorbidities Diabetes Cardiac Immune System Disorders Psychiatric Disorders Respiratory Disorders Vascular Disorders	16 (30.8) 11 (21.2) 11 (21.2) 20 (38.5) 10 (19.2) 21 (40.4)	27 (37.0) 14 (19.2) 11 (15.1) 26 (35.6) 12 (16.4) 32 (43.8)	0.57 0.82 0.48 0.85 0.81 0.72	56 (29.9) 45 (24.1) 40 (21.4) 72 (38.5) 45 (24.1) 101 (54.0)	41 (28.5) 35 (24.3) 26 (18.1) 41 (28.5) 32 (22.2) 63 (43.8)	0.80 1.0 0.49 0.06 0.79 0.08	0.30 0.38 0.69 0.66 0.20 0.48
Isolated Pathogens, n (%) MRSA Only MRSA Mixed Infection	36 (69.2) 16 (30.8)	53 (72.6) 20 (27.4)	0.69	142 (75.9) 45 (24.1)	105 (72.9) 39 (27.1)	0.61	0.48